Pathologic Thr$^{175}$ tau phosphorylation in CTE and CTE with ALS

Alexander J. Moszcynski, PhD, Wendy Strong, BSc, Kathy Xu, MSc, Ann McKee, MD, Arthur Brown, PhD, and Michael J. Strong, MD

Neurology® 2018;90:e380-e387. doi:10.1212/WNL.0000000000004899

Abstract

Objective
To investigate whether chronic traumatic encephalopathy (CTE) and CTE with amyotrophic lateral sclerosis (CTE-ALS) exhibit features previously observed in other tauopathies of pathologic phosphorylation of microtubule-associated protein tau at Thr$^{175}$ (pThr$^{175}$ tau) and Thr$^{231}$ (pThr$^{231}$ tau), and glycogen synthase kinase–3β (GSK3β) activation, and whether these pathologic features are a consequence of traumatic brain injury (TBI).

Methods
Tau isoform expression was assayed by western blot in 6 stage III CTE cases. We also used immunohistochemistry to analyze 5 cases each of CTE, CTE-ALS, and 5 controls for expression of activated GSK3β, pThr$^{175}$ tau, pThr$^{231}$ tau, and oligomerized tau within spinal cord tissue and hippocampus. Using a rat model of moderate TBI, we assessed tau pathology and phospho-GSK3β expression at 3 months postinjury.

Results
CTE and CTE-ALS are characterized by the presence of all 6 tau isoforms in both soluble and insoluble tau isolates. Activated GSK3β, pThr$^{175}$ tau, pThr$^{231}$ tau, and oligomerized tau protein expression was observed in hippocampal neurons and spinal motor neurons. We observed tau neuronal pathology (fibrillar inclusions and axonal damage) and increased levels of pThr$^{175}$ tau and activated GSK3β in moderate TBI rats.

Conclusions
Pathologic phosphorylation of tau at Thr$^{175}$ and Thr$^{231}$ and activation of GSK3β are features of the tauopathy of CTE and CTE-ALS. These features can be replicated in an animal model of moderate TBI.
Chronic traumatic encephalopathy (CTE) is a fatal neurodegenerative disease that is closely associated with traumatic brain injury (TBI). While TBI is typically associated with elite athletes, it also occurs as a result of both recreational and non-sport-related accidents. While there remains some controversy, a relationship between TBI and amyotrophic lateral sclerosis (ALS) has been observed, with between 4% and 6% of patients with CTE-TBI and amyotrophic lateral sclerosis (ALS) has been observed, with between 4% and 6% of patients with CTE demonstrating either clinical or neuropathologic features consistent with a diagnosis of ALS. CTE is an affective, behavioral, or cognitive disorder associated with repetitive head trauma that has a characteristic pattern of widespread neuronal and glial microtubule-associated tau (tau protein) deposition. In patients with concomitant ALS (CTE-ALS), motor neuron degeneration is also observed, including the presence of TDP-43 neuronal cytoplasmic inclusions.

The presence of a tauopathy in CTE and CTE-ALS raises the potential of a shared pathophysiology with ALS with cognitive impairment (ALS-CTE). Where tau is pathologically phosphorylated at threonine 175 (pThr175 tau) and threonine 231 (pThr231 tau), yielding pathogenic tau oligomers that subsequently assemble into insoluble pathologic tau fibrils. This process can be triggered by moderate TBI in a rodent.

To date, there have been no detailed studies of the phosphorylation state of tau in either CTE or CTE-ALS. Given this, we examined postmortem archival tissues from patients with CTE and patients with CTE-ALS for pThr175, pThr231, the active isoform of GSK3β (phospho-GSK3β [pGSK3β]), and tau oligomerization. We also examined whether this process can be triggered by moderate TBI in a rodent.

**Methods**

**Standard protocol approvals, registrations, and patient consents**

All studies on human tissues were conducted in accordance with the institutional ethics board standards at University Hospital (London, Canada) and Boston University School of Medicine (Massachusetts). All animal protocols were approved by the University of Western Ontario Animal Care Committee in accordance with the Canadian Council on Animal Care.

**CTE and CTE-ALS studies**

Microscope slides with 6-μm-thick hippocampal and spinal cord sections from neuropathologically confirmed cases of CTE (n = 5) and CTE-ALS (n = 5) in addition to 5 control cases with no neuropathologic evidence of a neurodegenerative disease state (cases 7–19) were used for immunohistochemical studies. An additional 6 cases (cases 1–6) were obtained as frozen tissue from anterior cingulate and temporal pole. All tissue and slides were obtained from the Veterans Affairs–Boston University–Concussion Legacy Foundation brain bank and were neuropathologically diagnosed as stage III CTE. Demographic data are summarized in table e-1 (http://links.lww.com/WNL/A99).

**Tau fractionation and western blot**

Tau protein was isolated from the anterior cingulate gyrus and the temporal pole of 6 stage III CTE cases and a single Alzheimer disease (AD) case as a control. Tau isolation, fractionation, dephosphorylation, and western blot were conducted as previously reported (e-Methods, http://links.lww.com/WNL/A100).

After transfer to nitrocellulose membranes, samples were probed for total tau with rabbit anti-tau T14/T46 antibodies (Thermo-Fisher, Burlington, Canada). After horseradish peroxidase–conjugated secondary antibody labeling, blots were visualized using enhanced chemiluminescence (PerkinElmer, Waltham, MA).

**Immunohistochemistry**

Six-micrometer paraffin-embedded sections from the hippocampus and spinal cord were analyzed for all cases. Immunohistochemistry was conducted using a series of antibodies (complete details in table e-2, http://links.lww.com/WNL/A99) that recognized pThr175 tau (21st Century, Marlboro, MA), pThr231 tau (Thermo-Fisher), and oligomeric tau (T22; EMD Millipore, Billerica, CA), and activated GSK3β (pTyr216; BD Biosciences, Mississauga, Canada). Antigen retrieval (10 mM sodium citrate, 0.05% Tween 20, pH 6.0) was conducted for all antibodies using a pressure cooker (2100 Retriever; Aptum Biologics, Southampton, UK, table e-2). Endogenous peroxidase was quenched with 3% hydrogen peroxide (VWR, Mississauga, Canada). Primary antibody incubation was performed at 4°C overnight in blocking buffer.
(5% bovine serum albumin, 0.3% Triton-X 100 in 1 × phosphate-buffered saline). After washing, secondary antibody (1:200 biotinylated immunoglobulin G) incubation was performed for 1 hour at room temperature (RT) in blocking buffer.

**Antigen**
Antibody complex was visualized with horseradish peroxidase according to the manufacturer’s instructions (Vectastain ABC kit, Vector Laboratories, Burlingame, CA), followed by substrate development with 3,3'-diaminobenzidine (DAB). Counterstaining was performed using Harris hematoxylin.

The extent of pathology was described semiquantitatively as previously reported using visualization with a 20× objective under light microscopy (Olympus BX45; Center Valley, PA).

Colocalizations and fluorescence staining
Double labeling was performed on sections from the hippocampus from one case per double-label experiment. Tau protein was probed with pThr$^{175}$ or oligomeric tau (T22) rabbit primary antibody overnight at 4°C and Alexa Fluor goat anti-rabbit 488 nm secondary (Thermo-Fisher) for 1 hour at RT. Rabbit anti-tau pThr$^{231}$ antibody was labeled using a Zenon primary antibody labeling kit with Alexa Fluor 555 nm dye (Thermo-Fisher) and probed for 1 hour at RT. Slides were visualized within 24 hours by confocal imaging on a Zeiss (Oberkochen, Germany) LSM 510 Meta NLO multiphoton confocal microscope. For colocalizations with pGSK3β, staining was performed with mouse anti-pTyr$^{216}$ GSK3β antibody (BD Biosciences) followed by secondary labeling with goat anti-mouse Alexa Fluor 633 nm dye (Invitrogen, Carlsbad, CA).

**In vivo studies**
Twelve adult female Sprague-Dawley rats were subjected to a 5-mm-diameter craniotomy followed by a single moderate head trauma (3.5 m/s, 2 mm deep, dwell time of 500 ms) using a cortical impactor (Precision Systems [Horsham, PA] model TBI 0310) (moderate TBI). After 3 months, all rats were killed by transcardiac perfusion with ice-cold saline after intraperitoneal injection with a lethal dose of Euthanyl. Six brains were drop-fixed in ice cold Bouin fixative (Thermo-Fisher) for immunohistochemical analysis while 6 were frozen on dry ice for neurochemical analysis. Bouin fixative was used to reduce artefactual tau pathology. After 24 hours of fixation, tissue was embedded in paraffin.

**Western blots**
Immunoblots were also performed using isolates from 6 moderate TBI rats and 4 age-matched controls (e-Methods, links.lww.com/WNL/A100). Briefly, brain tissue was homogenized in RIPA buffer containing protease and phosphatase inhibitors followed by concentration determination by modified Bradford assay (Bio-Rad, Hercules, CA). After immunoprecipitation of brain lysate for total tau (T46 antibody), the entire immunoprecipitation yield was run as a western blot (e-Methods). After transfer to nitrocellulose membrane, blots were probed with rabbit anti-pThr$^{175}$ tau. Gels were stripped for 30 minutes at 50°C and reprobed with rabbit anti–total tau (Abcam, Cambridge, UK). pGSK3β studies were performed on total brain lysate with mouse anti-GSK3β (BD Biosciences). Blots were visualized digitally by enhanced chemiluminescence (Perkin-Elmer) (Bio-Rad Chemidoc MP imaging system and acquired with ImageLab 5.2.1 software). Densitometry was conducted in ImageJ.

**Immunohistochemistry**
Six moderate TBI and 3 age-matched control rat brains were cut to 5–6 μm thickness and stained for pThr$^{175}$ tau, pThr$^{231}$ tau, and pTyr$^{216}$ GSK3β using the same antibodies and protocol used in human cases.

**Statistical analysis**
Statistical analyses were conducted using SigmaPlot 10.0 software. A one-way analysis of variance (ANOVA) was conducted following a Shapiro-Wilk test for normality. Post hoc Tukey test was conducted and a p value of 0.05 or lower was considered significant.

**Results**

**Western blot of human CTE**
Insoluble tau protein isolated from CTE cases contained all 6 isoforms in both phosphorylated and dephosphorylated isoforms. This was in contrast to the 3 isoforms constituting the paired helical filament motif in the insoluble fraction observed in a control AD case (figure 1).

**Immunohistochemistry in CTE cases**
pThr$^{175}$, pThr$^{231}$, and T22 immunoreactivity was observed in the hippocampal formation in all cases of CTE and CTE-ALS (table 1, figure 2A). This included tau-immunoreactive neurofibrillary tangles (NFTs) and dystrophic neurites throughout the CA1–4 regions and extending into the entorhinal cortex in all cases. Consistent with the limited pThr$^{175}$ tau non-neuronal pathology observed previously, oligodendroglial tau immunoreactivity was observed to a limited extent in 5 cases only. When present in control cases (3/5), tau immunoreactivity was observed only as faint immunoreactive
punctate neuronal staining in the absence of NFTs (figure 2B). No neuritic pathology was observed in controls.

We also observed pathologic tau deposition within the spinal cord regardless of the tau phosphoepitope studied (figure 2B). The presence of tau pathology was independent of whether the underlying pathologic diagnosis was CTE or CTE-ALS (table 1) and consisted of sparsely distributed NFTs in motor neurons and dystrophic neurites. In all cases, pathologic inclusions were minimal in number relative to a more diffuse immunoreactivity to pThr\textsuperscript{231} tau and pThr\textsuperscript{175} tau. No pThr\textsuperscript{175} tau staining was observed in control motor neurons, whereas pThr\textsuperscript{231} tau was observed, but when present, only as diffuse perikaryal staining of motor neurons. Lipofuscin staining was observed in some controls.

We observed a shift in the pattern of immunoreactivity of pGSK3\textbeta from primarily nuclear as observed in the control cases to a diffusely cytosolic pattern (figure e-1, http://links.lww.com/WNL/A98). This pattern was observed in hippocampal CA2 and spinal cord motor neurons in all CTE cases while only being present in occasional isolated cells in controls.

Double-immunolabeling of the hippocampus for both pThr\textsuperscript{175} tau and pThr\textsuperscript{231} tau consistently demonstrated colocalization of immunoreactivity to pThr\textsuperscript{231} tau with pThr\textsuperscript{175} immunoreactivity. However, the converse was not observed in that not all pThr\textsuperscript{231} tau immunoreactive hippocampal neurons were also pThr\textsuperscript{175}-positive, suggesting that only a subset of pThr\textsuperscript{231} tau pathology is also pThr\textsuperscript{175}-positive.\textsuperscript{10} This is consistent with our previous observations.\textsuperscript{10} We also observed colocalization of pThr\textsuperscript{231} tau and T22 (oligomerized tau), suggesting that oligomeric tau was a component of pThr\textsuperscript{231} tau pathology. Due to the nature of the antibodies, it was not possible to test for colocalization of pThr\textsuperscript{175} tau with T22 as they were raised in the same species, not purified and not compatible with the primary antibody labeling system available to us. While we can therefore only infer that pThr\textsuperscript{175} tau protein colocalizes with oligomeric tau as well, this inference is supported by our previous studies of a range of tauopathies in which serial sections were available for analysis.\textsuperscript{10} The inference is further supported by our finding that pThr\textsuperscript{175} tau immunoreactivity consistently colocalized with active GSK3\textbeta (figure 3).

**Table 1** Hippocampal and spinal cord pathology summary

<table>
<thead>
<tr>
<th>Antibody</th>
<th>CTE</th>
<th>CTE-ALS</th>
<th>Control</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Hippocampus semiquantitation (case-positive ratios)</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pThr\textsuperscript{175}</td>
<td>++++ (5/5)</td>
<td>++++++ (5/5)</td>
<td>+++ (3/5)</td>
</tr>
<tr>
<td>pThr\textsuperscript{231}</td>
<td>++++ (5/5)</td>
<td>++++++ (5/5)</td>
<td>±++ (3/5)</td>
</tr>
<tr>
<td>T22</td>
<td>+++ (5/5)</td>
<td>±+++ (5/5)</td>
<td>±++ (3/5)</td>
</tr>
<tr>
<td><strong>Spinal cord pathology case-positive ratios</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>pThr\textsuperscript{175}</td>
<td>3/5</td>
<td>3/5</td>
<td>0/5</td>
</tr>
<tr>
<td>pThr\textsuperscript{231}</td>
<td>4/5</td>
<td>4/5</td>
<td>2/5</td>
</tr>
<tr>
<td>T22</td>
<td>4/5</td>
<td>1/5</td>
<td>0/5</td>
</tr>
</tbody>
</table>

Abbreviations: ALS = amyotrophic lateral sclerosis; CTE = chronic traumatic encephalopathy.
The semiquantitative scale was applied to the field of interest as visualized under a 20× objective with the neuronal pathology quantified as follows: = none; ± = fewer than 5 inclusions; + = fewer than 10 inclusions; ++ = more than 20 inclusions with scattered distribution; +++ = more than 20 inclusions but with locally dense distribution; ++++ = more than 20 inclusions with a diffuse distribution.

**pThr\textsuperscript{175} and pThr\textsuperscript{231} expression in moderate TBI**

Both pThr\textsuperscript{175} and pThr\textsuperscript{231} tau neuronal immunoreactivity was observed in moderate TBI rat brains (figure 4). Of note, pThr\textsuperscript{175}-positive neuronal staining was observed in regions distant to the injury site mainly as axonal staining; however, no fibrillar inclusion-type pathology was observed in regions distant from the injury site. While pThr\textsuperscript{175} tau expression was elevated within the hemisphere ipsilateral to the injury,
pThr$^{175}$ tau expression in the contralateral hemisphere, while appearing to be increased, was not different from controls when normalized against total tau ($p = 0.05$ and 0.065, respectively, one-way ANOVA with $p = 0.008$ and $F = 5.757$). Diffuse pThr$^{231}$ staining was observed in healthy neurons. In contrast, pThr$^{231}$ tau immunoreactive pathology was only observed near the site of injury.

We investigated tau protein phosphorylation and GSK3$\beta$ activation by western blot (figure 4C). pTyr$^{216}$ GSK3$\beta$ was elevated in ipsilateral and contralateral hemispheres relative to uninjured controls ($p = 0.005$ and 0.001, respectively, one-way ANOVA with $p < 0.001$ and $F = 13.928$) when normalized against total GSK3$\beta$ (figure 4). Finally, we observed the same change in localization of pGSK3$\beta$ in moderate TBI rat brains as in CTE cases. This was quantified by blinded counts in which we observed an increase in diffuse expression of pTyr$^{216}$ GSK3$\beta$ in the injured hemisphere compared to uninjured control rats ($p = 0.01$ by Tukey post hoc test after one-way ANOVA $p = 0.004$ and $F = 7.559$; figure e-2, http://links.lww.com/WNL/A98).

Discussion

We have observed that both CTE and CTE-ALS are tauopathies in which pathologic tau aggregates contain aberrantly phosphorylated tau with immunoreactivity to both pThr$^{175}$ tau and pThr$^{231}$ tau. The presence of T22 immunoreactivity (recognizing oligomeric tau) is consistent with a pivotal role for phosphorylation at Thr$^{175}$ in the pathogenesis of CTE and CTE-ALS. The inference can be made on the basis of our previous study, which showed that pThr$^{175}$ tau pathology only occurs in pathologic conditions and that the expression of pThr$^{175}$ tau coincides with oligomerized tau in the same neuronal populations, as does the presence of pThr$^{231}$. Of note, this pathologic process of tau phosphorylation can be triggered experimentally in an in vivo model of moderate TBI and is consistent with a previously reported tauopathy induced by repeated trauma in a murine model of TBI, although this latter study did not investigate the physicochemical properties of the tauopathy. The finding that the tauopathy of CTE and CTE-ALS consists of the expression of all 6 tau isoforms in both the
soluble and insoluble tau isolates confirms that this process is biochemically distinct from the tauopathy of AD.

Consistent with our previous reports, pThr\(^{175}\) tau staining was only observed when other pathologic tau markers were also present\(^{10}\) and as such, pThr\(^{175}\) tau-positive staining in controls was restricted to those individuals with advanced age, where some tau pathology is expected in the hippocampal formation.\(^{25}\) Therefore, pThr\(^{175}\) tau appears to also be an indicator of toxicity and neuronal damage across a broad range of tauopathies and should be considered in future studies as a CSF or blood biomarker in the diagnosis of CTE\(^{26}\) either alone or in combination with other markers of neuronal injury such as 14-3-3\(^{27}\) or neurofilament proteins.\(^{28}\)

The tau isoform composition profile observed in CTE in this study and previously in ALSci\(^{20}\) in which all 6 tau isoforms are observed in the soluble and insoluble tau isolates is in distinction to that observed in a number of tauopathies, including AD (in which the pathogenic tau marker is the PHF triplet), corticobasal degeneration and progressive supranuclear palsy (4R tauopathies), and Pick disease (3R tauopathy).\(^{29–31}\) This could be interpreted as indicative that the tauopathy of CTE, CTE-ALS, and ALSci is a secondary event triggered in response to a primary neuronal injury. In both CTE and CTE-ALS, this can be postulated to be directly due to the TBI itself, a hypothesis that is supported by the in vivo moderate TBI experimental paradigm. While the trigger for the tauopathy of ALSci remains unknown, it is clear that once initiated, the presence of pThr\(^{175}\) leads to a cascade of events that culminates in neuronal death in vitro.\(^{16,32}\)

In relationship to our understanding of the pathophysiology of ALS, 4%–6% of patients with CTE also develop ALS
(CTE-ALS), a rate much higher than the incidence of ALS (2–3 per 100,000) in the general population. Unique to motor neuron degeneration associated with CTE-ALS is tau pathology in the spinal cord. The only other instance of a disseminated tauopathy in association with motor neuron degeneration is that observed in the previously hyperendemic Western Pacific variant of ALS, a variant of ALS recognized to be at the intersection of an environmental insult in an at-risk population.

While we have observed pathologic tau phosphorylation in the spinal cords of both patients with CTE and patients with CTE-ALS in this study, the variability observed warrants investigation on a larger cohort of cases with detailed rostrocaudal analysis to discern whether there is a correlation between motor symptom progression and regional tau deposition. We could not undertake such an analysis given the nature of tissue selection (cervical, thoracic, or lumbar for different cases). However, the absence of tau deposition in the spinal cords of patients with sporadic ALS suggests that the spinal motor neuron tauopathy of CTE-ALS is not an incidental finding or secondary to the primary neuronal injury of ALS. It is possible that tau protein phosphorylation and pathology begins early in the neurodegenerative process in CTE or CTE-ALS, in which case spinal cord pathology would be expected to precede symptom onset in patients who would otherwise develop motor impairment. In addition, given previous reports of TDP-43 deposition in the spinal cord of CTE-ALS, a much larger study investigating the correlation of TDP-43-positive neuronal cytoplasmic inclusions is required to bring clarity to the contributing pathologies concomitant to motor neuron death.

In these studies, we have observed pThr\textsuperscript{175} tau, in conjunction with pThr\textsuperscript{231} tau, oligomerized tau, and changes in active GSK3β localization consistent with a pathologic tauopathy driven by the aberrant phosphorylation of Thr\textsuperscript{175} tau in CTE and CTE-ALS. While we have shown that moderate TBI can directly drive this process, understanding how this induces pThr\textsuperscript{175} is the topic of current studies. Given our previous findings that this pathologic cascade of tau phosphorylation can be fully inhibited, and that this inhibition abolishes pThr\textsuperscript{175} tau-induced neuronal death, our work suggests that both CTE and CTE-ALS may be amenable to pharmacologic inhibition of GSK3β activation.

**Author contributions**
Alexander J. Moszczynski: contributed to design of all studies, conducted or assisted with all experimental procedures,

---

**Figure 4** Tau phosphorylated at threonine 175 (pThr\textsuperscript{175} tau) pathology in moderate traumatic brain injury (TBI)

At 3 months following moderate TBI, pThr\textsuperscript{175} tau pathology was observed. (A) Composite images of whole brain sections stained for pThr\textsuperscript{175} tau. Images were taken with a 4× objective. Inlay image taken with 40× objective. Arrow denotes site of injury. CA1 = CA1 region; CA3 = CA3 region; DG = dentate gyrus. Scale bar = 50 μm. (B) High-magnification images with moderate TBI show neuron and neuropathic pathology. Images were taken with 100× objective. Scale bar = 20 μm. (C) Western blots of pThr\textsuperscript{175} tau and total tau in ipsilateral and contralateral brain injuries. (D) Densitometry of western blots probed for pThr\textsuperscript{175} tau and total tau (pThr\textsuperscript{175}/total tau). (E) pTyr\textsuperscript{216} glycogen synthase kinase-3β (GSK3β) and total GSK3β (pTyr\textsuperscript{216}/total GSK3β) in ipsilateral and contralateral brain injuries. (F) Densitometry of western blots probed for pTyr\textsuperscript{216} GSK3β and total GSK3β. *p < 0.05. Contra = contralateral injury hemisphere; Ipsi = ipsilateral injury hemisphere.
performed all quantification and interpretation of data, wrote manuscript. Wendy Strong: performed tau fractionation experiments and western blot. Kathy Xu: performed animal surgeries. Ann McKee: contributed tissue to the study, performed pathologic diagnoses, edited manuscript. Arthur Brown: supervised and designed animal studies, edited manuscript. Michael J. Strong: supervised and designed all elements of the studies, edited manuscript.

Study funding
Research supported by an operating grant from the Ontario Neurodegenerative Disease Research Initiative and the Windsor-Essex ALS Society.

Disclosure
The authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Received July 8, 2017. Accepted in final form October 22, 2017.

References
Pathologic Thr\textsuperscript{175} tau phosphorylation in CTE and CTE with ALS

Alexander J. Moszczynski, PhD, Wendy Strong, BSc, Kathy Xu, MSc, Ann McKee, MD, Arthur Brown, PhD, and Michael J. Strong, MD

Cite as: Neurology\textsuperscript{©} 2018;90:e380–e387. doi:10.1212/WNL.0000000000004899

Study question
Are pathologic tau phosphorylation and glycogen synthase kinase-3β (GSK3β) activation observed in chronic traumatic encephalopathy (CTE) and CTE with amyotrophic lateral sclerosis (CTE-ALS), and can this be replicated in an experimental model of moderate traumatic brain injury (mTBI)?

Summary answer
Pathologic tau phosphorylation and GSK3β activation are observed in CTE, CTE-ALS, and modeled mTBI.

What is known and what this article adds
Pathologic tau phosphorylation and GSK3β activation occur in ALS with cognitive impairment (ALSci). By showing that they also occur in CTE and CTE-ALS, this study suggests that CTE and CTE-ALS may share pathophysiologic features with ALSci.

Participants and setting
This study analyzed samples from 6 patients with stage III CTE for Western blotting experiments. For further experiments, the study analyzed samples from 5 patients with CTE, 5 patients with CTE-ALS, and 5 healthy controls. All samples were obtained from the Veterans Affairs–Boston University–Concussion Legacy Foundation brain bank.

Design, size, and duration
Western blotting was used to analyze total tau isoform expression in anterior cingulate and temporal pole samples from the patients with stage III CTE. Immunohistochemistry was used to analyze the expression of phosphorylated or oligomeric tau and activated GSK3β in hippocampal and spinal cord samples from the other participants. Tau pathology and GSK3β activation were also evaluated at 3 months after experimental mTBI.

Primary outcomes
The primary outcomes were detecting Thr\textsuperscript{175}-phosphorylated tau, Thr\textsuperscript{231}-phosphorylated tau, oligomeric tau, and Tyr\textsuperscript{216}-phosphorylated GSK3β.

Main results and the role of chance
The isolates from the 6 patients with stage III CTE contained all 6 tau isoforms in both phosphorylated and dephosphorylated states. Thr\textsuperscript{175}-phosphorylated, Thr\textsuperscript{231}-phosphorylated, and oligomeric tau were observed in all hippocampal and spinal cord samples from patients with CTE or CTE-ALS. They were observed in hippocampal samples from 3 of the 5 healthy controls, but only faintly. Thr\textsuperscript{231}-phosphorylated tau was diffusely observed in spinal cord samples from the healthy controls. Cytosolic diffusion of Tyr\textsuperscript{216}-phosphorylated GSK3β was observed in hippocampal CA2 and spinal cord motor neurons from all patients with CTE or CTE-ALS but only occasionally observed in samples from the healthy controls. Three months following experimental mTBI, increased levels of Thr\textsuperscript{175}-phosphorylated tau and activated GSK3β were observed in association with tau neuronal pathology.

Bias, confounding, and other reasons for caution
This study included a small number of participants.

Generalizability to other populations
This study’s observations for CTE-ALS may not be generalizable to ALS without CTE, as only one other ALS subtype, one specific to the Western Pacific, features disseminated tauopathy in association with motor neuron degeneration.

Study funding/potential competing interests
This study was funded by the Ontario Neurodegenerative Disease Research Initiative and the Windsor–Essex ALS Society. The authors report no competing interests. Go to Neurology.org/N for full disclosures.

A draft of the short-form article was written by M. Dalefield, a writer with Editage, a division of Cactus Communications. The authors of the full-length article and the journal editors edited and approved the final version.